Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Related REGN
Benzinga's Top Upgrades, Downgrades For August 17, 2017
20 Stocks Moving In Monday's Pre-Market Session
Related SNY
Mylan's Stock Is No Longer A Buy According To Analysts At Argus
Where Does Zika Virus Vaccine Research Stand Now?
One of the '' Great Minds of Investing (GuruFocus)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers


Related Articles (REGN + SNY)

View Comments and Join the Discussion!